Cemiplimab’s prescription in the US excludes the patients with both EGFR+/ALK + NSCLC and ROS1 + NSCLC due to the two EMPOWER lung trials that did not include both types of NSCLC[17]. Here, EGFR is linked to non-small cell lung carcinoma.